CD19: Difference between revisions
From haematologyetc.co.uk
(Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :<span style="color:navy">'''Summary'''</span> :xxxx </div> <span style="color:navy">'''Normal expression and function'''</span> xxxxx <span style="color:navy">'''Diagnostic role'''</span> *xxxxx <span style="color:navy">'''Other relevant information:'''</span> xxxxx ---- <span style="color:navy">'''''SUMMARY TABLES'''''</span> <span style="font-...") |
No edit summary |
||
| Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
: | :CD19 expressed through most stages of B-cell development and is considered a pan b-cell marker i.e. present at early B-cell commitment until plasma cell stage | ||
| Line 14: | Line 14: | ||
<span style="color:navy">'''Normal expression and function'''</span> | <span style="color:navy">'''Normal expression and function'''</span> | ||
CD19 forms part of the normal B-cell receptor, and plays a major role in the recruiting and activating signalling proteins involved in B-cell activation. it reliably expressed by most normal B lymphocytes and also by follicular dendritic cells. Expression is acquired very early during normal B-cell development and tends to increase as B cells mature before becoming lost during the transition to plasma cells. | |||
Revision as of 22:04, 8 May 2023
- Summary
- CD19 expressed through most stages of B-cell development and is considered a pan b-cell marker i.e. present at early B-cell commitment until plasma cell stage
Normal expression and function
CD19 forms part of the normal B-cell receptor, and plays a major role in the recruiting and activating signalling proteins involved in B-cell activation. it reliably expressed by most normal B lymphocytes and also by follicular dendritic cells. Expression is acquired very early during normal B-cell development and tends to increase as B cells mature before becoming lost during the transition to plasma cells.
Diagnostic role
- xxxxx
Other relevant information:
xxxxx
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
| Expression in primitive cell types | |||||||
|---|---|---|---|---|---|---|---|
| AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
| Expression in mature B cell neoplasms | |||||||
|---|---|---|---|---|---|---|---|
| CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
| Expression in mature T cell neoplasms* | ||||||
|---|---|---|---|---|---|---|
| ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ||
Notes: xxxxx